Trinity Biotech Introduces CGM+: AI-Native Biosensor Platform for Next-Gen Health Monitoring

Trinity Biotech, a commercial-stage biotechnology company with a focus on diagnostics and diabetes management, has introduced its new flagship platform: CGM+. Now in the advanced stages of development, CGM+ is a next-generation continuous glucose monitoring system designed to meet the growing demands of AI-integrated healthcare and the booming global wearable market.

Unlike traditional CGMs, CGM+ integrates a minimally invasive electrochemical glucose sensor with real-time tracking of heart activity, body temperature, and physical movement—all in a single, modular wearable device. The data collected is optimized for AI-powered analytics, enabling a more comprehensive and personalized view of an individual’s metabolic and physiological health.

Built around Trinity Biotech’s proprietary needle-free glucose sensing technology, CGM+ reduces reliance on disposable components, helping lower long-term costs and environmental impact. The platform is designed to support both clinical applications and wellness-focused use cases, positioning it to serve as a bridge between regulated healthcare environments and the consumer health space.

“CGM+ is more than a monitoring device—it’s a data-driven engine for the AI health ecosystem,” said John Gillard, CEO of Trinity Biotech. “It’s designed to enable predictive and preventative care while creating new opportunities across diagnostics, digital health, and chronic disease management.”

CGM+ targets a large and fast-growing market intersection. The global CGM market is projected to reach $28.72 billion by 2030, while healthcare AI and wearable technologies are expected to exceed $200 billion and $260 billion, respectively, within the next decade. Trinity Biotech plans to commercialize CGM+ by mid-2026, with multiple revenue streams in view—including device sales, AI analytics subscriptions, and partnerships with healthcare providers, payers, and digital health platforms.

The company has recently completed a pre-pivotal trial of its enhanced glucose sensor and expects to share key results soon. As healthcare increasingly moves toward precision medicine and continuous monitoring, CGM+ positions Trinity Biotech as a serious contender in the future of AI-enabled care.